Increased Risk of Kidney Stones in Transgender Women and Gender-Diverse Adults on Gender-Affirming Hormone Therapy: Insights from a Large Database Study.
Eve Frangopoulos, Ziv Savin, Kavita Gupta, Vinay Durbhakula, Blair Gallante, William M Atallah, Mantu Gupta
{"title":"Increased Risk of Kidney Stones in Transgender Women and Gender-Diverse Adults on Gender-Affirming Hormone Therapy: Insights from a Large Database Study.","authors":"Eve Frangopoulos, Ziv Savin, Kavita Gupta, Vinay Durbhakula, Blair Gallante, William M Atallah, Mantu Gupta","doi":"10.1177/08927790251363612","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Transgender and gender-diverse (TGD) individuals represent a growing yet underrepresented group in medical literature. Estrogen and antiandrogens are essential in feminizing gender-affirming hormone therapy (f-GAHT) for individuals assigned male at birth (AMAB). This study examines f-GAHT effects on <i>de novo</i> nephrolithiasis risk in TGD individuals AMAB. <b><i>Methods:</i></b> This big data study utilizes medical records from the National Institutes of Health's <i>All of Us</i> database. The cohort includes patients AMAB who self-identified as non-binary, female, transgender women or had a relevant gender diagnosis. The cohort was divided into f-GAHT and non-f-GAHT groups. Cumulative incidence was calculated for each group. Participants were subdivided into estrogen-only f-GAHT (e-f-GAHT) and combined estrogen and antiandrogen f-GAHT (c-f-GAHT) groups. Univariate, unweighted multivariate, and weighted propensity score multivariate analyses were used to explore the association between nephrolithiasis and GAHT. <b><i>Results:</i></b> A total of 777 patients AMAB met our inclusion and exclusion criteria. The cumulative incidences of kidney stones were 10.3% and 4.8% in the f-GAHT and non-f-GAHT groups, respectively (<i>p</i> = 0.01). Kidney stone odds were 2.53 and 2.76 times greater in the unweighted and weighted regressions for f-GAHT compared with non-f-GAHT patients (<i>p</i> = 0.044 and <i>p</i> < 0.001, respectively). C-f-GAHT was associated with kidney stones in a weighted model (odds ratio [OR]: 2.63, 95% confidence interval [CI]: 1.44, 4.97, <i>p =</i> 0.002), whereas e-f-GAHT was not (OR = 1.88, 95% CI: 0.85, 4.32, <i>p</i> = 0.13). <b><i>Conclusions:</i></b> We observed a greater <i>de novo</i> incidence of nephrolithiasis among patients on f-GAHT. Antiandrogen therapy may work synergistically with estrogen to increase nephrolithiasis risk. Patients AMAB should be counseled about increased risk when starting f-GAHT, particularly if antiandrogens are included.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"1061-1067"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of endourology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08927790251363612","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Transgender and gender-diverse (TGD) individuals represent a growing yet underrepresented group in medical literature. Estrogen and antiandrogens are essential in feminizing gender-affirming hormone therapy (f-GAHT) for individuals assigned male at birth (AMAB). This study examines f-GAHT effects on de novo nephrolithiasis risk in TGD individuals AMAB. Methods: This big data study utilizes medical records from the National Institutes of Health's All of Us database. The cohort includes patients AMAB who self-identified as non-binary, female, transgender women or had a relevant gender diagnosis. The cohort was divided into f-GAHT and non-f-GAHT groups. Cumulative incidence was calculated for each group. Participants were subdivided into estrogen-only f-GAHT (e-f-GAHT) and combined estrogen and antiandrogen f-GAHT (c-f-GAHT) groups. Univariate, unweighted multivariate, and weighted propensity score multivariate analyses were used to explore the association between nephrolithiasis and GAHT. Results: A total of 777 patients AMAB met our inclusion and exclusion criteria. The cumulative incidences of kidney stones were 10.3% and 4.8% in the f-GAHT and non-f-GAHT groups, respectively (p = 0.01). Kidney stone odds were 2.53 and 2.76 times greater in the unweighted and weighted regressions for f-GAHT compared with non-f-GAHT patients (p = 0.044 and p < 0.001, respectively). C-f-GAHT was associated with kidney stones in a weighted model (odds ratio [OR]: 2.63, 95% confidence interval [CI]: 1.44, 4.97, p = 0.002), whereas e-f-GAHT was not (OR = 1.88, 95% CI: 0.85, 4.32, p = 0.13). Conclusions: We observed a greater de novo incidence of nephrolithiasis among patients on f-GAHT. Antiandrogen therapy may work synergistically with estrogen to increase nephrolithiasis risk. Patients AMAB should be counseled about increased risk when starting f-GAHT, particularly if antiandrogens are included.
期刊介绍:
Journal of Endourology, JE Case Reports, and Videourology are the leading peer-reviewed journal, case reports publication, and innovative videojournal companion covering all aspects of minimally invasive urology research, applications, and clinical outcomes.
The leading journal of minimally invasive urology for over 30 years, Journal of Endourology is the essential publication for practicing surgeons who want to keep up with the latest surgical technologies in endoscopic, laparoscopic, robotic, and image-guided procedures as they apply to benign and malignant diseases of the genitourinary tract. This flagship journal includes the companion videojournal Videourology™ with every subscription. While Journal of Endourology remains focused on publishing rigorously peer reviewed articles, Videourology accepts original videos containing material that has not been reported elsewhere, except in the form of an abstract or a conference presentation.
Journal of Endourology coverage includes:
The latest laparoscopic, robotic, endoscopic, and image-guided techniques for treating both benign and malignant conditions
Pioneering research articles
Controversial cases in endourology
Techniques in endourology with accompanying videos
Reviews and epochs in endourology
Endourology survey section of endourology relevant manuscripts published in other journals.